Advertisement
ADPT vs NTRA
Which Stock Would AI Choose? Adaptive Biotechnologies (ADPT) vs. Natera (NTRA) Stock Comparison
Key Takeaways
- Both ADPT and NTRA are diagnostics companies riding strong momentum in MRD (minimal residual disease) cancer testing, but they operate at very different scales.
- NTRA generates roughly ten times the quarterly revenue of ADPT and has already reached positive cash flow, giving it a more mature financial profile.
- ADPT is executing a planned separation of its MRD and Immune Medicine businesses, a catalyst that has fueled sharp recent share-price gains but also carries execution risk.
- Tickeron AI Verdict: NTRA — its combination of scale, momentum, and a broad catalyst pipeline gives it the stronger overall market positioning in this comparison.
- For more context, explore ADPT Major News and ADPT Today's Price Move, along with NTRA Major News and NTRA Today's Price Move.
- To see how AI trading systems are positioning across these and thousands of other tickers, explore Trending AI Robots.
Introduction
Investors evaluating precision-diagnostics growth stories frequently weigh ADPT against NTRA. Both companies have built their recent narratives around MRD (minimal residual disease) testing — technology that detects trace amounts of cancer after treatment — and both have delivered strong relative performance over the past year. Yet the two businesses differ sharply in size, profitability, and strategic direction. This comparison is most relevant to growth-oriented investors and traders seeking to understand which name offers the more consistent trend, the more durable catalysts, and the more favorable risk-reward profile in the current market environment.
ADPT Overview and Recent Performance
ADPT (Adaptive Biotechnologies) is a Seattle-based commercial-stage biotechnology company focused on the adaptive immune system. Its business is split between an MRD segment, anchored by its clonoSEQ assay, and an Immune Medicine segment pursuing drug discovery. MRD now accounts for roughly 95% of revenue, and the segment recently reached profitability on an adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) basis.
In recent quarters, ADPT has reported accelerating MRD revenue growth, raised its full-year 2026 MRD outlook, and announced plans to separate its MRD and Immune Medicine businesses by the end of 2026. A $300 million zero-coupon convertible notes offering added liquidity while also introducing potential future dilution. These developments have driven a sharp re-rating, with shares up well over 60% over a recent 90-day stretch. At the same time, the company remains loss-making on a GAAP (generally accepted accounting principles) basis, keeping cash burn and execution risk central to the bear case.
NTRA Overview and Recent Performance
NTRA (Natera) is an Austin, Texas-based diagnostics company specializing in cell-free DNA testing across oncology, women's health, and organ health. Its flagship Signatera test, a tumor-informed MRD assay, is the primary growth engine and is used by more than half of U.S. oncologists. Recent periods have featured record testing volumes, with oncology MRD volume rising more than 50% year over year.
NTRA has raised its full-year 2026 revenue guidance to between $2.85 billion and $2.91 billion and reported positive cash inflow alongside a narrowing loss per share. Regulatory and guideline milestones — including an FDA companion-diagnostic approval for Signatera in bladder cancer, approvals in Japan, IVDR (In Vitro Diagnostic Regulation) certification in Europe, and an NCCN Category 1 recommendation — have broadened the commercial runway. The stock has gained roughly 75% year to date, trading near its 52-week high, supported by a consensus "Strong Buy" analyst rating.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that collectively trade thousands of different tickers across varied strategies, timeframes, and risk profiles. Because market conditions shift, only a curated subset earns a place in the Trending AI Robots section, which highlights the bots best suited to the current environment. These systems differ meaningfully in trading style, holding period, performance metrics, and the specific tickers they follow, giving traders a range of approaches rather than a single one-size-fits-all signal. For investors comparing names like ADPT and NTRA, reviewing the Trending AI Robots page can offer additional, data-driven context on how automated systems are interpreting current momentum.
Head-to-Head Comparison
The most striking contrast is scale. NTRA produces roughly ten times ADPT's quarterly revenue and has a market capitalization several times larger. This scale underpins NTRA's broader test portfolio — spanning women's health and organ health alongside oncology — versus ADPT's heavier concentration in clonoSEQ-driven MRD revenue.
On profitability, NTRA has reached positive cash flow, whereas ADPT remains GAAP loss-making despite an improving adjusted EBITDA trajectory. On catalysts, NTRA benefits from a steady stream of regulatory and guideline wins, while ADPT's main near-term event is its business separation, a higher-risk structural change. Both names carry elevated valuations and reimbursement sensitivity, but NTRA's diversification and scale reduce single-product concentration risk relative to ADPT.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor NTRA in the current comparison. The stock exhibits a more consistent, longer-running uptrend, larger revenue base, positive cash flow, and a broader, more frequent catalyst pipeline than ADPT. While ADPT's recent momentum and separation catalyst are notable, its smaller scale and continued GAAP losses introduce greater relative uncertainty. These conditions point toward NTRA as the relatively stronger candidate on trend consistency, stability, and positioning, though both remain subject to valuation and reimbursement risks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADPT is a Hold and NTRA is a StrongBuy.
ADPT in downward trend: 10-day moving average moved below 50-day moving average on October 16, 2026
The 10-day moving average for ADPT crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ADPT moved out of overbought territory on September 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 23 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 63 cases where ADPT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.
ADPT moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
ADPT broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on ADPT as a result. In 77 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for ADPT just turned positive on October 27, 2026. Looking at past instances where ADPT's MACD turned positive, the stock continued to rise in 50 of 54 cases over the following month. The odds of a continued upward trend are 90%.
Following a +7.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADPT advanced for three days, in 236 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 170 of 188 cases where ADPT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (27.985) is normal, around the industry mean (65.876). P/E Ratio (-62.650) is within average values for comparable stocks, (3.542). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (13.966) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ADPT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Aroon Indicator for NTRA shows an upward move is likely
NTRA's Aroon Indicator triggered a bullish signal on October 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 286 similar instances where the Aroon Indicator showed a similar pattern. In 244 of the 286 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +6.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in 246 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
NTRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for NTRA moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 22 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 56%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 65 cases where NTRA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRA as a result. In 73 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for NTRA turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 36 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (29.986) is normal, around the industry mean (65.876). NTRA's P/E Ratio (-280.681) is considerably lower than the industry average of (3.542). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (17.857) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. NTRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ADPT | NTRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 22 Undervalued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 8 | |
SMR RATING 1..100 | 97 | 94 | |
PRICE GROWTH RATING 1..100 | 37 | 35 | |
P/E GROWTH RATING 1..100 | 64 | 86 | |
SEASONALITY SCORE 1..100 | 25 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (6) in the Biotechnology industry is in the same range as ADPT (22) in the Hospital Or Nursing Management industry. This means that NTRA’s stock grew similarly to ADPT’s over the last 12 months.
NTRA's Profit vs Risk Rating (8) in the Biotechnology industry is significantly better than the same rating for ADPT (100) in the Hospital Or Nursing Management industry. This means that NTRA’s stock grew significantly faster than ADPT’s over the last 12 months.
NTRA's SMR Rating (94) in the Biotechnology industry is in the same range as ADPT (97) in the Hospital Or Nursing Management industry. This means that NTRA’s stock grew similarly to ADPT’s over the last 12 months.
NTRA's Price Growth Rating (35) in the Biotechnology industry is in the same range as ADPT (37) in the Hospital Or Nursing Management industry. This means that NTRA’s stock grew similarly to ADPT’s over the last 12 months.
ADPT's P/E Growth Rating (64) in the Hospital Or Nursing Management industry is in the same range as NTRA (86) in the Biotechnology industry. This means that ADPT’s stock grew similarly to NTRA’s over the last 12 months.
| ADPT | NTRA | |
|---|---|---|
| RSI ODDS (%) | 7 days ago 77% | 2 days ago 56% |
| Stochastic ODDS (%) | 2 days ago 79% | 2 days ago 71% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 75% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 72% |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 76% |
| TrendMonth ODDS (%) | 2 days ago 84% | 2 days ago 79% |
| Advances ODDS (%) | 7 days ago 86% | 6 days ago 80% |
| Declines ODDS (%) | 2 days ago 85% | 2 days ago 75% |
| BollingerBands ODDS (%) | 2 days ago 86% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ADPT’s FA Score shows that 1 FA rating(s) are green while NTRA’s FA Score has 2 green FA rating(s).
- ADPT’s FA Score: 1 green, 4 red.
- NTRA’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ADPT’s TA Score shows that 4 TA indicator(s) are bullish while NTRA’s TA Score has 3 bullish TA indicator(s).
- ADPT’s TA Score: 4 bullish, 6 bearish.
- NTRA’s TA Score: 3 bullish, 5 bearish.
Price Growth
ADPT (@Medical Specialties) experienced а -4.61% price change this week, while NTRA (@Medical Specialties) price change was -6.42% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.31%. For the same industry, the average monthly price growth was -4.38%, and the average quarterly price growth was +42.93%.
Reported Earning Dates
ADPT is expected to report earnings on Nov 04, 2026.
NTRA is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Medical Specialties (-1.31% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
NTRA and
Correlation & Price change
A.I.dvisor indicates that over the last year, NTRA has been loosely correlated with ADPT. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if NTRA jumps, then ADPT could also see price increases.
| Ticker / NAME | Correlation To NTRA | 1D Price Change % | ||
|---|---|---|---|---|
| NTRA | 100% | -8.54% | ||
| ADPT - NTRA | 55% Loosely correlated | -5.93% | ||
| NEO - NTRA | 55% Loosely correlated | -5.12% | ||
| GH - NTRA | 54% Loosely correlated | -4.51% | ||
| ISRG - NTRA | 53% Loosely correlated | +1.12% | ||
| TMO - NTRA | 48% Loosely correlated | -2.06% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FKU | 55.57 | 1.02 | +1.86% |
| First Trust United Kingdom AlphaDEX Fund (FKU) | |||
| DMO | 9.77 | 0.09 | +0.93% |
| Western Asset Mortgage Opportunity Fund | |||
| LFAI | 142.38 | N/A | N/A |
| LifeX 2050 Longevity Income ETF (LFAI) | |||
| QMOM | 69.62 | -1.38 | -1.94% |
| Alpha Architect U.S. Quantitative Momentum ETF (QMOM) | |||
| FENY | 36.89 | -1.59 | -4.13% |
| Fidelity MSCI Energy Index ETF (FENY) | |||